MA5-26990

antibody from Invitrogen Antibodies

Targeting: SRSF9 SFRS9, SRp30c

Western blot

Antibody data

Submit

Validation data

SRSF9 protein structure - MA5-26990 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded adenocarcinoma of human breast tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded carcinoma of human prostate tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded human lymph node tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded adenocarcinoma of human colon tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded human kidney tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded carcinoma of human kidney tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded carcinoma of human lung tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded human pancreas tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded carcinoma of human pancreas tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded carcinoma of human thyroid tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry was performed on paraffin-embedded human prostate tissue. To expose target proteins, heat-induced epitope retrieval by Tris-EDTA, pH8.0. Following antigen retrieval, tissues were probed with a SRSF9 monoclonal antibody (Product # MA5-26990) at a dilution of 1:150.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 SRSF9 regulates AS of Caspase-2 pre-mRNA. ( A )-(Upper) Schematic AS representation of endogenous Caspase-2 pre-mRNA. Primers used in RT-PCR are shown with arrows. (Middle) RT-PCR analysis of endogenous Caspase-2 pre-mRNA from untreated, ns- and SRSF9 shRNA treated cells. GAPDH was used as a loading control. Results of immunoblotting with anti-SRSF9 in these cells are shown, with alpha-tubulin, SRSF1 and SRSF3 as a controls. (Lower) Statistical differences of RT-PCR with p values are shown, ****, p < 0.0001 and **, p < 0.01. ( B )-(Upper) Schematic representation of Caspase-2 minigene. Exons are shown with boxes and introns are shown with lines. Lengths of each part are shown. Primers used in RT-PCR analysis are shown with arrows. (Middle) RT-PCR analysis of Caspase-2 minigene from untreated, empty vector treated and SRSF9 expression plasmid treated HeLa and HEK293T cells. GAPDH was used as a loading control. Immunoblotting with anti-SRSF9 antibody is shown, with alpha-tubulin as a control. (Lower) Statistical differences of RT-PCR analysis are shown, ****, p < 0.0001; and **, p < 0.01.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 SRSF9 targets downstream exon to regulate AS of Caspase-2. ( A )-(Upper) Schematic representation of D-10 minigene. Deleted sequences in the minigene are shown. D-10 was produced based on the deletion mutant of D9-2. (Middle) RT-PCR analysis of D-10 minigene in untreated, empty vector treated and SRSF9 expression plasmids treated HeLa cells. (Lower) Statistical differences are shown. ( B )-(Upper) Sequences of wild type, M1 and M2 minigenes are shown. (Middle) RT-PCR analysis of M1 and M2 minigenes untreated, empty vector treated and SRSF9 expression plasmids treated HeLa cells are shown. (Lower) Statistical differences of RT-PCR analysis are shown. ( C )-(Upper) Sequences of biotin-labeled oligonucleotides (wild type, M1 and M2) are shown. (Lower) Results of RNA-pulldown and immunoblotting for wild type, M1 and M2 with anti-SRSF9 and anti-SRSF3 antibodies are shown.